Data completeness
3/8 — Basic
Drug data last refreshed 26m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIABNI is a CD20-directed monoclonal antibody biosimilar to rituximab developed by Amgen, approved in December 2020. It is indicated for B-cell malignancies and autoimmune conditions where CD20+ B cells are pathogenic. The drug works by binding to CD20 antigen on B cells, triggering cytolysis and immune-mediated cell death.
$0.003BPart D
PeakRIABNI is in peak commercial phase with modest Part D penetration ($3M), indicating opportunity for commercial expansion within a mature biosimilar segment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on RIABNI at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.